Quantitative Proteomics For Biomarker Discovery and Validation: Prostate Cancer Case Study

Posted by

SELECTBIO

The application of a wide range of proteomics methods is leading to the discovery of large numbers of potential new protein biomarkers. These markers promise more informed diagnosis of disease, monitoring of disease progression and response to therapeutic intervention and have the potential to inform clinical decision making for the most effective use of existing drugs and treatments and selection of most appropriate therapeutic regimes. However, in the last decade few new  proteomics discovered biomarkers have reached approved clinical utility. The challenges faced in the biomarker development process will be described. Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer-related deaths in men. At present, serum prostate-specific antigen (PSA) is the only molecular biomarker widely used in the diagnosis and management of patients with PCa but it cannot distinguish indolent from aggressive disease. There is an important need for clinically relevant biomarkers which will